Doxycycline for Hidradenitis Suppurativa Treatment
For pediatric patients ≥8 years and adults with HS requiring systemic antibiotics, use oral doxycycline 100 mg twice daily, though it is not a first-line monotherapy and performs best as adjunctive treatment or in combination regimens. 1, 2
Key Evidence and Positioning
The most recent 2025 North American guidelines strongly recommend oral doxycycline for pediatric patients 8 years and older with HS 1. However, the evidence base reveals important limitations:
- Doxycycline 100 mg twice daily was studied in the PIONEER adalimumab trials but was not independently linked to better outcomes in either the adalimumab or placebo arms 2
- This means doxycycline alone has weak evidence for efficacy as monotherapy
- The 2019 guidelines note that tetracycline monotherapy showed only 30% reduction in abscesses with no significant patient-reported outcome improvements 2
Preferred Antibiotic Regimens
Clindamycin 300 mg + rifampin 300 mg, both twice daily for 8-12 weeks, is the superior first-line antibiotic combination with response rates of 71-93% across 187 patients 2. This combination substantially outperforms doxycycline monotherapy.
Alternative Doxycycline Formulations
Recent research suggests modified-release doxycycline (MR-DC) 40 mg once daily may offer comparable efficacy to standard doxycycline 100 mg twice daily with better tolerability:
- HiSCR50 achieved in 75.8% at 12 weeks with MR-DC 40 mg 3
- Head-to-head comparison showed HiSCR in 64% (MR-DC 40 mg) vs 60% (standard doxycycline 100 mg BID) 4
- Lower antimicrobial resistance risk and fewer adverse events with the subantimicrobial dose 3, 4
- Relapse occurred in 33% at 6 months, indicating need for maintenance strategies 3
Clinical Algorithm
When to use doxycycline:
- Mild-to-moderate HS (Hurley stage I-II)
- As adjunctive therapy with biologics in moderate-to-severe disease
- In pediatric patients ≥8 years when tetracyclines are indicated
- When clindamycin-rifampin is contraindicated or not tolerated
Predictors of better response:
- Shorter disease duration (most significant predictor) 3
- Lower baseline IHS4 score
- Lower BMI
- Absence of pubic/genital involvement 3
Critical Pitfalls
⚠️ Do not use doxycycline as monotherapy expecting high response rates - the evidence shows it underperforms compared to clindamycin-rifampin combination 2
⚠️ Avoid in children <8 years due to tooth discoloration and bone development concerns 1, 5
⚠️ Counsel patients on photosensitivity and advise liberal fluid intake to prevent esophageal irritation 5
⚠️ In severe/Hurley stage III disease, doxycycline alone is inadequate - these patients need biologics or more aggressive combination therapy 2, 6
Practical Dosing
- Standard regimen: Doxycycline 100 mg PO twice daily 2
- Alternative low-dose: Modified-release doxycycline 40 mg PO once daily 3, 4
- Duration: Typically 8-12 weeks, can be repeated intermittently 2
- Absorption: Not significantly affected by food or milk, unlike other tetracyclines 5
Role in Contemporary Management
The 2026 joint AAD-HSF guidelines give doxycycline a conditional recommendation 6, reflecting its modest standalone efficacy. Doxycycline functions best as bridge therapy, adjunctive treatment with biologics, or in patients with contraindications to more effective antibiotic combinations 7, 8, 9.
For inflammatory control in moderate-to-severe HS, biologics (adalimumab, secukinumab, bimekizumab) are superior 6, 8, with antibiotics serving supportive roles or managing acute flares 7.